TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Data-driven Quality Improvement in Primary Care: Cluster Randomised Controlled Trial to Test the Effectiveness of a Multifaceted Intervention in Reducing High Risk Prescribing of Non-steroidal Anti-inflammatory Drugs and Antiplatelet Agents
Brief Summary: A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2
B: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
C: Arm Label: Music Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Music Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Music Therapy; Assigned to Arm(s): Music Therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to interest | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to function | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to both interest and function | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Activity matched to interest; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Activity matched to function; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Activity matched to both interest and function; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Data-driven Quality Improvement in Primary Care: Cluster Randomised Controlled Trial to Test the Effectiveness of a Multifaceted Intervention in Reducing High Risk Prescribing of Non-steroidal Anti-inflammatory Drugs and Antiplatelet Agents
Brief Summary: A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.


Options:
A: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
B: Arm Label: Music Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Music Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Music Therapy; Assigned to Arm(s): Music Therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to interest | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to function | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to both interest and function | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Activity matched to interest; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Activity matched to function; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Activity matched to both interest and function; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Data-driven Quality Improvement in Primary Care: Cluster Randomised Controlled Trial to Test the Effectiveness of a Multifaceted Intervention in Reducing High Risk Prescribing of Non-steroidal Anti-inflammatory Drugs and Antiplatelet Agents
Brief Summary: A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.


Options:
A: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
B: Arm Label: Guided Care; Type: EXPERIMENTAL; Interventions: Behavioral: Guided Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Guided Care; Assigned to Arm(s): Guided Care
C: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
D: Arm Label: PREPARE; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE website | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Advance directive | Intervention Type: BEHAVIORAL; Name: PREPARE website; Assigned to Arm(s): PREPARE | Intervention Type: BEHAVIORAL; Name: Advance directive; Assigned to Arm(s): CONTROL

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Data-driven Quality Improvement in Primary Care: Cluster Randomised Controlled Trial to Test the Effectiveness of a Multifaceted Intervention in Reducing High Risk Prescribing of Non-steroidal Anti-inflammatory Drugs and Antiplatelet Agents
Brief Summary: A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.


Options:
A: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: Quality improvement strategies; Assigned to Arm(s): N/A
D: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Osteoarthritis (OA), a common disabling condition, is the commonest type of arthritis worldwide.Pain is the leading symptom and is often chronic in na. Current treatment options have had limited symptomatic effect and are associated with significant side effects. Duloxetine, a selective serotonin norepinephrine reuptake inhibitor has been demonstrated to have, besides its antidepressant properties, a centrally acting analgesic effect.

The aim of the present study was to investigate the efficacy of duloxetine in reducing pain in older adults with knee OA.

288 patients aged 65 years and above with ACR clinical and radiographic criteria of primary knee OA attending the outpatient clinic of our institution were enrolled in this study. All patients underwent a physical examination and where questioned about the number of flares. Exclusion criteria included any inflammatory, autoimmune, psychiatric illness and morbid obesity. Patients were randomized 1:1. One hundred and forty four received 60mg/day of duloxetine HCL and 144 received placebo together with their usual therapy for 16 weeks. The primary outcome measure was pain reduction. Secondary outcome measures included improvements in physical functioning scores. Pain was assessed using the Brief Pain Inventory (BPI) and Visual Analogue pain Scale, (VAS, 0-100 mm). Functional assessment using the self-reported physical function as measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), WOMAC pain and stiffness scores and the Geriatric Depression Scale (GDS) was conducted. Alterations in dosage of analgesic/NSAID drugs used were recorded. Safety and tolerability were also assessed. Data was collected at baseline and at monthly intervals for 4 months. All staff involved in data collection was blinded to the treatment assignment groups.


Options:
A: Intervention Type: DRUG; Name: duloxetine HCL; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice
Brief Summary: Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Extended Release tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin Extended Release tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: gabapentin; Type: EXPERIMENTAL; Interventions: Drug: gabapentin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): gabapentin | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Open Label; Type: N/A; Interventions: N/A | Arm Label: Open label; Type: N/A; Interventions: N/A
D: Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled, Assessor-blind, Parallel Groups, Multi-national, Multi-centre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Women Undergoing an ART Programme
Brief Summary: This trial investigates the effects of several doses of FE 999049 in women undergoing IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.


Options:
A: Arm Label: AMH-group; Type: EXPERIMENTAL; Interventions: Other: AMH-analysis | Arm Label: Non-AMH-group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: AMH-analysis; Assigned to Arm(s): AMH-group
B: Arm Label: CONSORT Dosing; Type: EXPERIMENTAL; Interventions: Drug: GONAL f® prefilled pen | Arm Label: Standard Dosing; Type: ACTIVE_COMPARATOR; Interventions: Drug: GONAL f® prefilled pen | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): CONSORT Dosing | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): Standard Dosing
C: Arm Label: 450 IU daily dose of gonadotrophin; Type: ACTIVE_COMPARATOR; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Arm Label: 600 IU daily dose of gonadotrophin; Type: EXPERIMENTAL; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Intervention Type: DRUG; Name: menotropins for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin | Intervention Type: DRUG; Name: urofollitropin for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin
D: Arm Label: 5.2 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 6.9 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 8.6 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 10.3 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 12.1 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 11 µg FbM (150 IU); Type: ACTIVE_COMPARATOR; Interventions: Drug: Gonal - F | Intervention Type: DRUG; Name: FE 999049; Assigned to Arm(s): 10.3 µg, 12.1 µg, 5.2 µg, 6.9 µg, 8.6 µg | Intervention Type: DRUG; Name: Gonal - F; Assigned to Arm(s): 11 µg FbM (150 IU)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled, Assessor-blind, Parallel Groups, Multi-national, Multi-centre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Women Undergoing an ART Programme
Brief Summary: This trial investigates the effects of several doses of FE 999049 in women undergoing IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.


Options:
A: Arm Label: CONSORT Dosing; Type: EXPERIMENTAL; Interventions: Drug: GONAL f® prefilled pen | Arm Label: Standard Dosing; Type: ACTIVE_COMPARATOR; Interventions: Drug: GONAL f® prefilled pen | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): CONSORT Dosing | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): Standard Dosing
B: Arm Label: 5.2 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 6.9 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 8.6 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 10.3 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 12.1 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 11 µg FbM (150 IU); Type: ACTIVE_COMPARATOR; Interventions: Drug: Gonal - F | Intervention Type: DRUG; Name: FE 999049; Assigned to Arm(s): 10.3 µg, 12.1 µg, 5.2 µg, 6.9 µg, 8.6 µg | Intervention Type: DRUG; Name: Gonal - F; Assigned to Arm(s): 11 µg FbM (150 IU)
C: Arm Label: Highly Purified Menotrophin; Type: EXPERIMENTAL; Interventions: Drug: Highly purified menotrophin | Arm Label: Recombinant FSH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Recombinant FSH | Intervention Type: DRUG; Name: Highly purified menotrophin; Assigned to Arm(s): Highly Purified Menotrophin | Intervention Type: DRUG; Name: Recombinant FSH; Assigned to Arm(s): Recombinant FSH
D: Arm Label: 450 IU daily dose of gonadotrophin; Type: ACTIVE_COMPARATOR; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Arm Label: 600 IU daily dose of gonadotrophin; Type: EXPERIMENTAL; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Intervention Type: DRUG; Name: menotropins for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin | Intervention Type: DRUG; Name: urofollitropin for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Interventions to Teach Respiratory Inhaler techNique (E-TRaIN)
Brief Summary: The purpose of this study is to evaluate the relative effectiveness of two different ways to teach subjects while hospitalized how to use respiratory inhalers and to follow-up after discharge home from the hospital to determine durability of the education.

Teach-to-Goal (TTG) education employs instruction followed by patient "teach-back," then repeated cycles of learning and assessment until a skill is mastered. By contrast, Brief Intervention (BI) education only consists of providing the patient with verbal and written instruction.

The investigators hypothesize that hospital-based TTG compared to BI increases a patient's ability to retain instructions on respiratory inhaler technique. The investigators will test this hypothesis separately for the MDI and Diskus® devices after discharge.


Options:
A: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: COPD evidence based care pathway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPD evidence based care pathway; Assigned to Arm(s): Pathway
B: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone (50/500 µg) BID fixed combination | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers | Intervention Type: DRUG; Name: Salmeterol / Fluticasone (50/500 µg) BID fixed combination; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers; Assigned to Arm(s): arm 2
C: Intervention Type: DRUG; Name: Formoterol Fumurate inhalation solution 20 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg; Assigned to Arm(s): N/A
D: Arm Label: Educational Intervention A; Type: EXPERIMENTAL; Interventions: Behavioral: Teach-To-Goal | Arm Label: Educational Intervention B:; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Intervention Type: BEHAVIORAL; Name: Teach-To-Goal; Assigned to Arm(s): Educational Intervention A | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Educational Intervention B:

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study
Brief Summary: The purpose of this study is to examine differences in the long-term effects of immediate versus delayed cord clamping at birth on developmental outcomes of our study infants at 18-22 months corrected age.


Options:
A: Arm Label: 1-Delayed Cord Clamping (DCC); Type: EXPERIMENTAL; Interventions: Procedure: delayed umbilical cord clamping | Arm Label: 2-Immediate Cord Clamping (ICC); Type: ACTIVE_COMPARATOR; Interventions: Other: Immediate cord clamping | Intervention Type: PROCEDURE; Name: delayed umbilical cord clamping; Assigned to Arm(s): 1-Delayed Cord Clamping (DCC) | Intervention Type: OTHER; Name: Immediate cord clamping; Assigned to Arm(s): 2-Immediate Cord Clamping (ICC)
B: Arm Label: Immediate cord clamping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: delayed cord clamping | Arm Label: Delayed Cord Clamping; Type: EXPERIMENTAL; Interventions: Procedure: delayed cord clamping | Intervention Type: PROCEDURE; Name: delayed cord clamping; Assigned to Arm(s): Delayed Cord Clamping, Immediate cord clamping
C: Arm Label: Umbilical Cord Milking; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Umbilical Cord Milking | Arm Label: Delayed Cord Clamping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Delayed Cord Clamping | Intervention Type: PROCEDURE; Name: Umbilical Cord Milking; Assigned to Arm(s): Umbilical Cord Milking | Intervention Type: PROCEDURE; Name: Delayed Cord Clamping; Assigned to Arm(s): Delayed Cord Clamping
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Delayed Cord Clamping | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate Cord Clamping | Intervention Type: PROCEDURE; Name: Delayed Cord Clamping; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Immediate Cord Clamping; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Brief Summary: Study participants with primary breast cancer will receive a standard chemotherapy with an anthracycline and a taxane as well as trastuzumab in case of HER2-positive tumors at doses and duration in concordance to current treatment guidelines. Patients will be receive and benefit in addition currently not in the neoadjuvant setting registered medication as lapatinib or bevacizumab of which significant increases of cure (pCR) rates have been reported in previous phase III studies. Patients randomized to carboplatin will receive in addition to the described backbone therapies a potentially active agent which suggested synergy of efficacy with chemotherapies as well as targeted agents. Patients might have the risk of an increase in toxicities due to the added agents and will have additional burden due to investigations required for study participation. However, due to the severity of the underlying disease and the high risk of relapse and death due to the stage of disease, this increase in toxicity and burden appears less relevant compared to the potential higher efficacy and finally cure rate by the incorporated treatments.


Options:
A: Arm Label: T-DM1; Type: EXPERIMENTAL; Interventions: Drug: T-DM1 | Arm Label: T-DM1 + endocrine therapy; Type: EXPERIMENTAL; Interventions: Drug: T-DM1 | Arm Label: Trastuzumab + endocrine therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab | Intervention Type: DRUG; Name: T-DM1; Assigned to Arm(s): T-DM1, T-DM1 + endocrine therapy | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab + endocrine therapy
B: Arm Label: Induction Therapy; Type: EXPERIMENTAL; Interventions: Other: Induction therapy | Intervention Type: OTHER; Name: Induction therapy; Assigned to Arm(s): Induction Therapy
C: Arm Label: Doxorubicin-Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Cisplatin | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Doxorubicin-Cyclophosphamide | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Doxorubicin-Cyclophosphamide
D: Arm Label: Carboplatin + background treatment; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: background treatment | Arm Label: background treatment only; Type: ACTIVE_COMPARATOR; Interventions: Drug: background treatment | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + background treatment | Intervention Type: DRUG; Name: background treatment; Assigned to Arm(s): Carboplatin + background treatment, background treatment only

Answer: D